renal failure – Page 6 – Communicable Diseases Research

The clinical effect of Nano micelles containing curcumin as a therapeutic supplement in patients with COVID-19 and the immune responses balance changes following treatment: A structured summary of a study protocol for a randomised controlled trial

COVID-19 환자의 치료 보조제로 커큐민을 함유한 나노 미셀의 임상 효과 및 치료 후 면역 반응 균형 변화: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-10-222022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial

입원한 COVID-19 환자의 결과 개선에 대한 파모티딘의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-10-132022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] Alanine Alanine transaminase alcoholism All participant All participants allergies allergy allocation approved ARMS aspartate Aspartate transaminase assigned assumption Bandar Abba Bandar Abbas baseline Blinding block randomization blood count Care Chronic kidney disease clearance clinical clinical trial clinical trials code Committee company comparator Comparator group complete blood count concealed control group control groups COVID-19 COVID-19 patient COVID-19 patients creatinine creatinine clearance criteria Dasatinib dialysis discharge dissemination dosage drug therapy electrocardiogram element eligibility criteria End-stage renal disease ethics committee Evidence evidence of excluded expected Famotidine G6PD Glucose Glucose 6 phosphate grouping groups Hepatitis hepatitis C Hospitalized Immunocompromised Immunocompromised patients Infection Intervention Kidney disease Lactate lactate dehydrogenase lead limit Liver disease Local lung infiltration maximum Medical Science Medical Sciences moderate need for dialysis Neratinib normal limit number objective online tool oral contraceptives outcome outcome assessor outcome assessors oxygen oxygen saturation Ozanimod participant Patient patients patients with COVID-19 Pazopanib PCR test pharmaceutical Pharmaceutical Company phosphate Placebo placebo-controlled porphyria positive Pregnancy protocol psoriasis random randomisation randomised randomised controlled trial randomized clinical trial Randomly randomly divided receive recruitment Registered registry renal renal disease renal failure reported Research question researcher respiration rate responsible Rilpivirine Sample size sample size calculation sequence sequence information single-blind Siponimod Standard study drug Study protocol subject submitted technology temperature the ethics committee therapy title Tizanidine transaminase Treatment treatment group Treatment protocol treatment protocols Trial registration two group two groups university Version website were measured written consent
[DOI] 10.1186/s13063-020-04773-6 PMC 바로가기 [Article Type] Letter

Medication Reconciliation: The Foundation of Medication Safety for Patients Requiring Dialysis

Article

Published on 2020-09-112024-09-04
Journal: American journal of kidney diseases : the official [Category] 대상포진,

[키워드] adverse drug events Medication discrepancy patient safety Quality improvement renal failure
[DOI] 10.1053/j.ajkd.2020.07.021 PMC 바로가기 [Article Type] Article

24 Hours: A Case of Multiorgan Failure Associated With COVID-19

Internal Medicine

Published on 2020-08-312022-10-31
Journal: Cureus [Category] COVID-19,

[키워드] 24 hour acidosis Acute kidney injury acute respiratory distress Admission AKI ARDS caused COVID-19 Cytokine storm death died failure female Hemodialysis Hospital admission Injury less mechanism Mortality MOST progression renal renal failure Risk factors severe metabolic syndrome the disease the patient
[DOI] 10.7759/cureus.10149 PMC 바로가기 [Article Type] Internal Medicine

muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial

코비드-19-실험 약물 및 기전(TACTIC-E)으로 입원한 ICu 전 환자에 대한 다중 암 치료 연구: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-07-312022-08-13
Journal: Trials [Category] SARS, 임상,

[키워드] able to swallow adaptive Adaptive trial added Admission age Ambrisentan Analysis approved Arm ARMS balloon pump balloon pump) baseline benefit Biomarker blinded Blinding calculated Cambridge Cambridge University Hospitals NHS Foundation Trust can not cardiac cardiovascular complications cells clearance clinical endpoint Clinical endpoints clinical picture clinically Combination comparator comparison Complete Composite Course COVID-19 COVID-19 infection creatinine creatinine clearance CRP Dapagliflozin Data analysis Day death defined demonstrated determine diabetes Diagnosis discretion disease dissemination drug drugs ECMO EDP1815 Efficacy element enrolled envelope EU Clinical Trial EU Clinical Trials EudraCT Evidence evidence of exclusion criteria Experimental drugs failure feature fixed foundation Gault Gender group hypertension immunomodulation immunomodulatory incidence include Inclusion independent independent data monitoring committee Inotropes Intervention Invasive mechanical ventilation investigator Laboratory late stage male mechanism membrane neutrophil Neutrophils NHS number objective Occurrence on admission once daily Open-label open-label trial opinion option Organ failure organ support Other outcome Oxygenation pandemic Parallel Arm participant Patient patients with COVID-19 performed phase platform Platform trial positive positive COVID-19 predicted Primary outcome principal investigator progression protocol Radiographic radiological randomisation randomised Randomized controlled trial recruited reduce Registered related disease renal renal failure risk Sample size severity Standard of care status stratified Study protocol subject Support tablets the patient therapy Treatment treatment arm Trial Trial registration triggered Trust university website
[DOI] 10.1186/s13063-020-04618-2 PMC 바로가기 [Article Type] Letter

Clinical characteristics of 82 cases of death from COVID-19

코로나19 사망자 82명의 임상적 특징

Research Article

Published on 2020-07-092022-08-13
Journal: PLoS ONE [Category] Biochemistry, COVID-19, MERS, SARS,

[키워드] Admission age Alanine alanine aminotransferase aspartate Aspartate aminotransferase association C-reactive protein Cancer cardiac failure cause of death caused Cerebrovascular disease Characteristics clinical Clinical characteristics Clinical data Comorbidities Comorbidity COVID-19 cytokine cytokine release Cytokine release syndrome D-dimer Data collection death death case detected patients develop diabete diabetes diagnosed died disease electronic medical record followed by forms heart disease hemorrhage Hemorrhagic hemorrhagic damage hypertension ICU IL-6 initial symptom initial symptoms IQR laboratory-confirmed Lactate lactate dehydrogenase Local lymphocyte lymphopenia male mechanical ventilation support median age median time medical records MOST Most patient Most patients neutrophil Neutrophil-to-lymphocyte ratio neutrophilia Older on admission other organs oxygen Patient patients Pneumonia proportion remained renal renal damage renal failure respiratory Respiratory failure SARS-CoV-2 SARS-COV-2 infection Sepsis severe disease single center Spread systemic immune-inflammation index the median the patient thrombocytopenia treated virus Wuhan Wuhan local hospital’ Wuhan, China
[DOI] 10.1371/journal.pone.0235458 PMC 바로가기 [Article Type] Research Article

Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients – mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial

ICu 전 환자의 Covid-19에 대한 용도 변경 면역조절 약물 - Covid-19로 입원한 ICu 전 환자에 대한 다중 암 치료 연구 – 용도 변경 약물(TACTIC-R): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-07-082022-08-13
Journal: Trials [Category] SARS, 임상,

[키워드] Administered Admission age Analysis Arm ARMS balloon pump balloon pump) Baricitinib baseline blinded Blinding calculated Cambridge Cambridge University Hospitals NHS Foundation Trust can not candidate cardiac clearance clinical picture college comparator comparison Complete COVID-19 infection creatinine creatinine clearance CRP Data analysis Data monitoring committee Day death defined determine diabetes Diagnosis discharge disease dissemination dose drug Drug evaluation Efficacy element enrolled envelope EU Clinical Trial EU Clinical Trials EudraCT event exclusion criteria feature fixed foundation Gault Gender hypertension IDMC immunomodulatory immunomodulatory drug immunomodulatory drugs Immunomodulatory therapies immunomodulatory therapy incidence include Inclusion independent data monitoring committee initial Inotropes interim analysis Intervention intravenously Invasive mechanical ventilation investigator ISRCTN late stage Local male membrane neutrophil Neutrophils NHS number objective on admission once daily Open-label open-label trial opinion Organ failure organ support outcome Oxygenation participant Patient phase Platform trial positive positive COVID-19 predicted Primary outcome progression Prophylaxis protocol Radiographic radiological randomisation randomised randomised controlled trial Ravulizumab recruited recruitment reduce reduced regimen Registered related disease renal renal failure Repurposed drugs risk Sample size scalability selected severity SOC stage 2 Standard of care status stratified Study protocol subject Support Toxicity treatment arm Trial Trial registration triggered Trust university university hospital Venous Thromboembolism website
[DOI] 10.1186/s13063-020-04535-4 PMC 바로가기 [Article Type] Letter

Pharmaceuticals and Medical Device Agency approval summary: Amenamevir for the treatment of herpes zoster

의약품 및 의료기기청 승인 요약: 대상포진 치료를 위한 아메나메비르

Review

Published on 2020-07-012023-06-01
Journal: The Journal of dermatology [Category] 대상포진, 두창, 수두, 홍역,

[키워드] amenamevir helicase-primase inhibitor herpes zoster pharmaceuticals and medical device agency renal failure
[DOI] 10.1111/1346-8138.15393 [Article Type] Review

Fatal Outcome in a Kidney-Pancreas Transplant Recipient With COVID-19

Internal Medicine

Published on 2020-06-182022-10-31
Journal: Cureus [Category] COVID-19,

A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 age analogue anticipated assigned Asymptomatic blinded bpm Characteristics clinical trial comparator components Contact Controlled trial coronavirus disease COVID-19 COVID-19 symptom COVID19 Date deficiency develop Diabetes Mellitus Diagnosis disease dissemination dose double-blind drug Efficacy Efficiency eight element enrolled enrolment EU Clinical Trial evaluate evaluate the effect exclusion criteria experimental arm female participant Final Glucose haloperidol healthcare healthcare worker Healthcare workers hematological Hemodialysis hepatitis B Hereditary high risk history HIV HIV infection hospital hypersensitivity IgM/IgG immune immunosuppressive incidence Inclusion Infection Inflammatory cytokine Intervention less lymphopenia male melatonin men and women multicenter myasthenia gravis number objective outcome participant Patient PCR Placebo polymerase chain post-symptom onset Premenopausal Prevent prophylactic treatment Prophylaxis protocol Ramón randomisation randomised randomised controlled trial randomization Randomized Rapid test receiving recruited renal failure Research Retinitis rheumatoid arthritis risk RT-PCR Sample size SARS-CoV 2 SARS-CoV-2 SARS-COV-2 infection SAS version 9.4 secondary sequence Seroconversion severe COVID-19 severity of COVID-19 Sex Spain Spanish statistical status stratified study drug Study protocol symptomatic infection symptomatic SARS-CoV-2 infection Treatment Trial two-arm parallel ulcerative colitis understanding urinary pregnancy test Vasculitis website weight women
[DOI] 10.1186/s13063-020-04436-6 PMC 바로가기 [Article Type] Letter